Understanding the Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma - Episode 5

The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

EP. 1: Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma
EP. 2: Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular Lymphoma
EP. 3: Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma
EP. 4: Dr. Kahl on Differences in Mechanisms of Action of PI3K Inhibitors in Follicular Lymphoma
Now Viewing
EP. 5: The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

Related Content:

Understanding the Evolving Role of PI3K Inhibitors in the Treatment of Follicular LymphomaScientific Interchange & Workshop
Best Practices in Treating Early-Stage NSCLC
An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer